Jaggi S, presented a session at IDF World Diabetes Congress 2025 from 7th -10th April 2025 in Bangkok. CGM has revolutionized the management of diabetes and is now widely acceptable. CGM technology has transformed diabetes care by offering real-time glucose monitoring and trend analysis. Smartphone apps and cloud connectivity enhance CGM data accessibility and clinical decision-making. Recent innovations include closed-loop systems or hybrid artificial pancreas device/AID that use CGM data to automatically adjust insulin delivery. Eversense CGM system, fully implantable, functions for 90 days; have also reported a 365-day sensor.
Interstitial fluid-based sensors involve extracting ISF from subcutaneous tissue to monitor blood glucose using reverse iontophoresis (RI) and microneedle (MN) technology are being developed. Smartwatch style CGM that uses disposable microneedle biosensor capsules are still in development, focused on combining lifestyle and glucose monitoring.
Accu-Check SmartGuide obtained CE approval in 2024 for its 14-day glucose sensor and app-incorporates advanced algorithms capable of predicting the risk of low BG within 30 min, forecasting glucose trends up to 2 hours ahead identifying potential nighttime hypoglycemia risks. OTC 14 day CGM system approved by USFDA 2024 for general glucose tracking even without diabetes; no prescription needed.
Conclusion:
